US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NewcelX Ltd.

2.64

-0.0600-2.22%

Volume:12.61K

Turnover:33.43K

Market Cap:12.03M

PE:-0.61

High:2.77

Open:2.68

Low:2.63

Close:2.70

52wk High:30.80

52wk Low:1.89

Shares:4.56M

Float Shares:4.56M

Volume Ratio:1.41

T/O Rate:0.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.3226

EPS(LYR):-1.7386

ROE:--

ROA:-155.19%

PB:-0.88

PE(LYR):-1.52

Loading ...

Overview Company News Filings

NewcelX AG Releases Updated Corporate Presentation

NewcelX AG Reports Positive Results from International Study on Stem Cell-Derived Islet Therapy for Type 1 Diabetes

Newcelx Appoints DR. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

THOMSON REUTERS

Press Release: NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

Newcelx Strengthens Scientific Advisory Board With Appointment of Jeremy Shefner, Md, Phd, Chief Medical Officer at the Barrow Neurological Institute

THOMSON REUTERS

Press Release: NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board

BRIEF-NewceIX CEO Issues Letter To Shareholders

NLS Pharmaceutics and Kadimastem merge to form NewcelX

Newcelx- Co Has $25 Mln Eloc, Well-Capitalized for 12 Months

THOMSON REUTERS

Newcelx CEO Issues Letter to Shareholders

THOMSON REUTERS

NLS Pharmaceutics AG Releases Investor Presentation Document

Newcelx Provides Business and Strategic Roadmap Update Following Closing of Merger With NLS Pharmaceutics Ltd.

THOMSON REUTERS

Top Premarket Decliners

MT Newswires Live

NLS Pharmaceutics AG trading halted, news pending

BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of Merger

NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX

Press Release: NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger

NLS Pharmaceutics and Kadimastem Secure Continued BIRD Foundation Support Following Merger

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCEL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":2.64,"timestamp":1771874735242,"preClose":2.7,"halted":0,"volume":12614,"delay":0,"changeRate":-0.02222222222222224,"floatShares":4558400,"shares":4558400,"eps":-4.322621,"marketStatus":"Trading","change":-0.06,"latestTime":"02-23 14:30:59 EST","open":2.68,"high":2.77,"low":2.63,"amount":33430.404868000005,"amplitude":0.051852,"askPrice":2.66,"askSize":100,"bidPrice":2.6,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.322621,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":2.7,"preHourTrading":{"tag":"盘前","latestPrice":2.5,"preClose":2.7,"latestTime":"08:00 EST","volume":12,"amount":30,"timestamp":1771851605083,"change":-0.2,"changeRate":-0.074074,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.7,"preClose":2.7,"latestTime":"19:34 EST","volume":35,"amount":96.15,"timestamp":1771634050806,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.405573},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":4558400,"roa":"-155.19%","roe":"--","lyrEps":-1.738588,"volumeRatio":1.405573,"shares":4558400,"dividePrice":0,"high":2.77,"amplitude":0.051852,"preClose":2.7,"low":2.63,"week52Low":1.89,"pbRate":"-0.88","week52High":30.799,"institutionHeld":0,"latestPrice":2.64,"eps":-4.322621,"divideRate":0,"volume":12614,"delay":0,"ttmEps":-4.322621,"open":2.68,"prevYearClose":1.9,"prevWeekClose":2.7,"prevMonthClose":2.6,"prevQuarterClose":1.9,"fiveDayClose":2.77,"twentyDayClose":2.67,"sixtyDayClose":3.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCEL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCEL","date":"2026-02-20","current":-0.610741,"percent":0.459459,"low":-2.085416,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"high":-0.442896,"avg":-0.729666,"sd":0.240999,"marketCap":12581123},"quantilePoints":[{"date":"2025-10-31","current":-2.085416,"twenty":-2.085416,"median":-2.085416,"eighty":-2.085416,"marketCap":39937082.48},{"date":"2025-11-07","current":-0.993097,"twenty":-1.495376,"median":-1.229626,"eighty":-1.098389,"marketCap":18917268},{"date":"2025-11-14","current":-0.808829,"twenty":-1.253274,"median":-0.970727,"eighty":-0.876223,"marketCap":15635236},{"date":"2025-11-21","current":-0.750891,"twenty":-1.145695,"median":-0.878334,"eighty":-0.814355,"marketCap":14358890},{"date":"2025-11-28","current":-0.957951,"twenty":-1.045743,"median":-0.867781,"eighty":-0.806793,"marketCap":18279095},{"date":"2025-12-05","current":-0.856292,"twenty":-0.972009,"median":-0.871696,"eighty":-0.812974,"marketCap":16455744},{"date":"2025-12-12","current":-0.781666,"twenty":-0.995845,"median":-0.875612,"eighty":-0.812974,"marketCap":15179398},{"date":"2025-12-19","current":-0.635834,"twenty":-0.972009,"median":-0.85736,"eighty":-0.781019,"marketCap":12353204},{"date":"2025-12-26","current":-0.613233,"twenty":-0.957493,"median":-0.83848,"eighty":-0.693066,"marketCap":11988534},{"date":"2026-01-02","current":-0.442896,"twenty":-0.955117,"median":-0.833152,"eighty":-0.615876,"marketCap":8660918},{"date":"2026-01-09","current":-0.513637,"twenty":-0.941907,"median":-0.808829,"eighty":-0.589968,"marketCap":10074015},{"date":"2026-01-16","current":-0.561129,"twenty":-0.915578,"median":-0.78535,"eighty":-0.566624,"marketCap":11122442},{"date":"2026-01-23","current":-0.610165,"twenty":-0.913462,"median":-0.76547,"eighty":-0.561129,"marketCap":12125285},{"date":"2026-01-30","current":-0.576613,"twenty":-0.882218,"median":-0.6841,"eighty":-0.565731,"marketCap":11623863},{"date":"2026-02-06","current":-0.601541,"twenty":-0.878334,"median":-0.628521,"eighty":-0.570197,"marketCap":12034117},{"date":"2026-02-13","current":-0.627168,"twenty":-0.875612,"median":-0.627168,"eighty":-0.572325,"marketCap":12717874},{"date":"2026-02-20","current":-0.632256,"twenty":-0.869347,"median":-0.627168,"eighty":-0.573006,"marketCap":12581123}],"updateTime":1771875059038},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607808112","title":"NewcelX AG Releases Updated Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2607808112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607808112?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:02","pubTimestamp":1769688131,"startTime":"0","endTime":"0","summary":"NewcelX AG has released an updated corporate presentation ahead of key spring 2026 investor and partnering conferences, highlighting its strategic focus on Type 1 Diabetes cell therapy and recent additions to its Scientific Advisory Board and leadership team. The updated presentation is available on the Company's website at: Corporate Presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL6l1Sz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU2362541273.HKD","IE00B7KXQ091.USD","LU2279689827.SGD","LU0251132253.USD","IE00BJJMRZ35.SGD","LU1267930573.SGD","IE00BFSS7M15.SGD","LU0820561909.HKD","LU1791710400.SGD","LU2357305700.SGD","LU1551013342.USD","SG9999018857.SGD","LU0316494557.USD","LU0107464264.USD","LU0114720955.EUR","LU2089984988.USD","LU0149725797.USD","LU0943347566.SGD","LU0965508806.USD","LU2028103732.USD","IE00BSNM7G36.USD","IE00B1BXHZ80.USD","LU0256863811.USD","LU1914381329.SGD","LU0456855351.SGD","LU0738911758.USD","IE00B19Z9505.USD","IE00BWXC8680.SGD","LU0689472784.USD","LU2112291526.USD","LU0353189763.USD","LU0320765059.SGD","LU1023059063.AUD","LU0094547139.USD","LU1732800096.USD","LU1119994496.HKD","LU0187121727.USD","BK4581","LU0795875169.SGD","LU0234572021.USD","IE00BN29S564.USD","LU0310800379.SGD","LU1496350502.SGD","LU2125154935.USD","LU0912757837.SGD","IE00B4JS1V06.HKD","IE0009355771.USD","LU0708995401.HKD","LU0965509101.SGD","LU0557290698.USD","LU2236285917.USD","LU2491050071.SGD","SG9999014898.SGD","IE00B19Z9Z06.USD","BK4154","LU0128525689.USD","LU0672654240.SGD","IE00B19Z3581.USD","LU0820562030.AUD","LU0097036916.USD","LU1323610961.USD","LU0949170772.SGD","SGXZ31699556.SGD","LU2468319806.SGD","LU2242649171.HKD","LU1066051225.USD","LU1674673691.USD","LU1061106388.HKD","SG9999017495.SGD","LU1035773651.USD","BK4534","LU1291159041.SGD","BK4139","LU2361045086.USD","LU1934455277.USD","IE00B4R5TH58.HKD","LU0109391861.USD","LU1506573853.SGD","LU2264538146.SGD","LU1551013425.SGD","IE00BJT1NW94.SGD","LU0128525929.USD","IE00BFTCPJ56.SGD","IE00BKVL7J92.USD","SG9999018865.SGD","IE0002141913.USD","LU1670628061.USD","IE00B2B36J28.USD","IE00B775H168.HKD","LU0011850046.USD","LU0496365809.HKD","LU0048584097.USD","LU2111349929.HKD","UNHG","LU0882574055.USD","LU0053666078.USD","LU2552382058.USD","LU0211326755.USD","LU2362540622.SGD","LU1854104046.USD","LU0683600562.USD","LU1066051498.USD","SG9999002232.USD","LU1261432733.SGD","LU1267930490.SGD","LU1778281490.HKD","NCEL","BK4533","LU2089284900.SGD","LU2461242641.AUD","LU1066053197.SGD","IE00BZ1G4Q59.USD","SG9999014914.USD","IE00B7SZLL34.SGD","LU2271345857.HKD","LU0787776722.HKD","IE00BJJMRX11.SGD","LU0708994859.HKD","IE0004445015.USD","LU0052756011.USD","LU0823416689.USD","LU2125154778.USD","IE00BZ9MQY76.HKD","LU1720051108.HKD","LU0198837287.USD","LU1718418525.SGD","LU1854103824.USD","LU1153585028.USD","LU0029864427.USD","LU0122379950.USD","LU2324357040.USD","LU0861579265.USD","LU0266013472.USD","LU0310799852.SGD","SG9999001176.USD","IE00B894F039.SGD","LU0820561818.USD","BK4532","LU1069347547.HKD","LU0661504455.SGD","LU2361044949.HKD","LU1064131342.USD","LU0795875086.SGD","SG9999013999.USD","LU1934455863.HKD","LU0528227936.USD","SGXZ99366536.SGD","LU0203345920.USD","LU2089283258.USD","LU2244417387.USD","LU2347655156.SGD","LU1003077747.HKD","LU2491050154.USD","LU1066051811.HKD","LU1267930730.SGD","IE00B19Z9P08.USD","LU0158827781.USD","LU1988902786.USD","LU0965509283.SGD","LU0345770993.USD","IE00BFXG1179.USD","IE000M9KFDE8.USD","LU0211326839.USD","SGXZ57979304.SGD","LU1267930227.SGD","LU1037948897.HKD","LU1814569148.SGD","LU1074936037.SGD","LU1732799900.SGD","LU0058720904.USD","LU0976567544.SGD","LU0077335932.USD","BK4588","BK4585","LU0211327993.USD","LU0432979614.USD","LU2087625088.SGD","LU0211328371.USD","IE00B19Z3B42.SGD","LU1037948541.HKD","UNHW","LU2211815571.USD","LU1057294990.SGD","IE00B19Z8X17.USD","LU0310800965.SGD","LU1720051017.SGD","SG9999014906.USD","SGXZ81514606.USD","LU0289739699.SGD","LU1934455194.USD","LU0545039389.USD","LU1989771016.USD","SG9999001176.SGD","LU1674673428.USD","SG9999014880.SGD","LU0354030438.USD","LU2360032135.SGD","LU1548497426.USD","IE00BJJMRY28.SGD","IE0005OL40V9.USD","LU0342679015.USD","LU0965509010.AUD","LU1983299246.USD","LU0553294199.USD","LU1084165304.USD","LU2133065610.SGD","LU2361044865.SGD","LU2491049909.HKD","LU2552382215.SGD","LU1791710582.SGD","LU2362541513.USD","LU0203347892.USD","SGXZ51526630.SGD","LU0354030511.USD","IE00B19Z8W00.USD","LU0079474960.USD","LU0353189680.USD","LU0238689110.USD","LU2552382132.HKD","IE0004445239.USD","LU0345770308.USD","LU2023251221.USD","SG9999002224.SGD","LU1670627923.USD","IE00BKPKM429.USD","LU0417517546.SGD","LU0158827948.USD","IE00BFSS8Q28.SGD","IE00B1XK9C88.USD","IE0002270589.USD"],"gpt_icon":0},{"id":"2602514996","title":"NewcelX AG Reports Positive Results from International Study on Stem Cell-Derived Islet Therapy for Type 1 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514996","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514996?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:01","pubTimestamp":1768219262,"startTime":"0","endTime":"0","summary":"NewcelX AG has announced positive results from an international collaborative research study exploring advanced biomaterial approaches for the delivery of stem cell-derived islets in the treatment of Type 1 Diabetes. The study focused on combining stem cell biology with innovative delivery and immune protection strategies, aiming to achieve functional insulin secretion without the need for systemic immunosuppression. Results from the study have already been reported and contribute to the ongoing development of NewcelX’s investigational therapy, IsletRx. The research was supported by the Australian Foundation for Diabetes Research, the National Stem Cell Foundation of Australia, and Breakthrough T1D.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8ckSXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2601688573","title":"Newcelx Appoints DR. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2601688573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601688573?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUAC2JNMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2601088508","title":"Press Release: NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2601088508","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601088508?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614400,"startTime":"0","endTime":"0","summary":"ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd.  , a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board .Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap pharma company, where he oversees the strategic development of next-generation diabetes technologies, clinical programs, and real-world evidence initiatives. His background includes connected-care innovation, advanced insulin-management systems, and the integration of therapeutic and digital solutions to enhance patient outcomes.NewCelX Ltd.  is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodege","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2584664029","title":"Newcelx Strengthens Scientific Advisory Board With Appointment of Jeremy Shefner, Md, Phd, Chief Medical Officer at the Barrow Neurological Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=2584664029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584664029?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:00","pubTimestamp":1763380802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA6YBVXX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NCEL"],"gpt_icon":0},{"id":"2584628832","title":"Press Release: NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute","url":"https://stock-news.laohu8.com/highlight/detail?id=2584628832","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584628832?lang=en_us&edition=fundamental","pubTime":"2025-11-17 20:00","pubTimestamp":1763380800,"startTime":"0","endTime":"0","summary":"ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd.  , a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board .\"We are very pleased to welcome Prof. Shefner to our Scientific Advisory Board,\" said Ronen Twito, Executive Chairman & CEO of NewcelX. \"His leadership in ALS research and trial methodology strengthens our ability to bring advanced therapies to patients living with this devastating disease. His appointment underscores our commitment to scientific excellence and rigorous clinical execution.\". NewcelX Ltd.  is a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform merges advanced stem-cell technologies with neuroscience expertise to deliver scalable, life-changing treatmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","R","BK4196","NCEL","BK4232","MD","BK4022"],"gpt_icon":0},{"id":"2581206295","title":"NLS Pharmaceutics Names Prof. Tamir Ben-Hur to NewcelX Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2581206295","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581206295?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:03","pubTimestamp":1762430625,"startTime":"0","endTime":"0","summary":"NewcelX Ltd. has announced that Professor Tamir Ben-Hur, a leading neurologist and expert in neuroimmunology and stem-cell-based regenerative medicine, will join its Scientific Advisory Board. This development follows the unification of Kadimastem Ltd.'s advanced stem-cell platforms and clinical programs with NLS Pharmaceutics Ltd.'s expertise in central nervous system therapeutics, forming the foundation of NewcelX. The company aims to advance transformative cell therapies for neurodegenerative and metabolic diseases, including ALS and diabetes. Professor Ben-Hur's appointment is seen as a strong endorsement of the combined scientific vision and clinical ambitions of the new entity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6VHvTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","NLSP","BK4139","BK4007"],"gpt_icon":0},{"id":"2580273558","title":"BRIEF-NewceIX CEO Issues Letter To Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2580273558","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580273558?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:04","pubTimestamp":1762257890,"startTime":"0","endTime":"0","summary":"BRIEF-NewceIX CEO Issues Letter To ShareholdersNov 4 (Reuters) - NLS Pharmaceutics AG NCEL.O:NEWCELX CEO ISSUES LETTER TO SHAREHOLDERSNEWCELX- CO HAS $25 MILLION ELOC, WELL-CAPITALIZED FOR 12 MONTHSSource text: ID:nPn8Z2JDvaFurther company coverage: NCEL.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG089:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2580735331","title":"NLS Pharmaceutics and Kadimastem merge to form NewcelX","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735331","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735331?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:03","pubTimestamp":1762257807,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics Ltd. and Kadimastem Ltd. have completed a merger to form NewcelX Ltd., a Swiss clinical-stage biopharmaceutical company. The newly combined company brings together Kadimastem's advanced cell-therapy platforms with NLS's expertise in neuroscience and small-molecule drug development, aiming to create innovative treatments for neurodegenerative and metabolic diseases. In connection with the merger, the companies raised approximately $9 million through equity financing and warrant exercises, with additional financial support from a $25 million Equity Line of Credit facility. NewcelX has outlined plans for multiple clinical milestones over the next year, including a Phase 2a clinical study in ALS and expansion of its therapeutic pipeline. The update was disclosed by NewcelX Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL2kcDjF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","NCEL","NLSP"],"gpt_icon":0},{"id":"2580735386","title":"Newcelx- Co Has $25 Mln Eloc, Well-Capitalized for 12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735386?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:01","pubTimestamp":1762257674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG089:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2580059733","title":"Newcelx CEO Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2580059733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580059733?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:01","pubTimestamp":1762257674,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG089:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2580215150","title":"NLS Pharmaceutics AG Releases Investor Presentation Document","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215150","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215150?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:26","pubTimestamp":1762176387,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL5yXb3w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NLSP","NCEL","BK4007"],"gpt_icon":0},{"id":"2580121515","title":"Newcelx Provides Business and Strategic Roadmap Update Following Closing of Merger With NLS Pharmaceutics Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2580121515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580121515?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:26","pubTimestamp":1762176365,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUABG1HS1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4139"],"gpt_icon":0},{"id":"2580213697","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213697","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213697?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:04","pubTimestamp":1762175083,"startTime":"0","endTime":"0","summary":"UniQure (QURE) shares were 65% lower pre-bell Monday after the company said it believes that the US Food and Drug Administration no longer considers its Huntington's disease therapy data adequate to s","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALVO","QURE","LU0320765992.SGD","LU0889565916.HKD","BK4139","CLPT","NCEL","BK4082","LU0109394709.USD"],"gpt_icon":0},{"id":"2579107926","title":"NLS Pharmaceutics AG trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579107926?lang=en_us&edition=fundamental","pubTime":"2025-10-31 07:50","pubTimestamp":1761868215,"startTime":"0","endTime":"0","summary":"19:50 EDT NLS Pharmaceutics (NLSP) AG trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nls-pharmaceutics-ag-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nls-pharmaceutics-ag-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AG","BK4210","NCEL","BK4007","NLSP"],"gpt_icon":0},{"id":"2579108707","title":"BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579108707","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579108707?lang=en_us&edition=fundamental","pubTime":"2025-10-31 05:12","pubTimestamp":1761858761,"startTime":"0","endTime":"0","summary":"BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of MergerOct 30 (Reuters) - NLS Pharmaceutics AG NLSP.O:NLS PHARMACEUTICS LTD. AND KADIMASTEM LTD. ANNOUNCE COMPLETION OF MERGERSource text: ID:nPn1P34QdaFurther company coverage: NLSP.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUABWSBVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLSPW","NCEL","BK4007","NLSP"],"gpt_icon":0},{"id":"2579108639","title":"NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX","url":"https://stock-news.laohu8.com/highlight/detail?id=2579108639","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579108639?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:57","pubTimestamp":1761857856,"startTime":"0","endTime":"0","summary":"The latest update is out from NLS Pharmaceutics ( ($NLSP) ). On October 30, 2025, NLS Pharmaceutics Ltd. completed its merger with Kadimastem Ltd.,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-complete-merger-to-form-newcelx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-complete-merger-to-form-newcelx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NCEL","BK4007","NLSP"],"gpt_icon":0},{"id":"2579172809","title":"Press Release: NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579172809","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579172809?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:15","pubTimestamp":1761855300,"startTime":"0","endTime":"0","summary":"Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol \"NCEL\". ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/ --. Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX said, \"With the launch of NewcelX, we have brought together exceptional science and a global leadership team with the potential to change lives. The completion of the merger and the commencement of trading on Nasdaq mark a significant milestone that reflects the trust and confidence of our shareholders and investors, and I am deeply grateful for their support as we take this next step forward together. We are now preparing to initiate our Phase 2a clinica","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":[".IXIC","NLSP","NCEL","BK4585","MNQmain","USAW.SI","NVIW.SI","BK4555","BK4588","QID","TQQQ","BK4007","QLD","USJW.SI","BK4099","NLSPW","NQmain","SQQQ","03160","BK4604","PSQ","TSYW.SI","TM"],"gpt_icon":1},{"id":"2579908191","title":"NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579908191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579908191?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:57","pubTimestamp":1761739079,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics ( ($NLSP) ) has shared an update. On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NCEL","NLSP","BK4007","ITOL","POST","BK4212"],"gpt_icon":0},{"id":"2579977259","title":"NLS Pharmaceutics and Kadimastem Secure Continued BIRD Foundation Support Following Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579977259","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579977259?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:31","pubTimestamp":1761737478,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics Ltd. and Kadimastem Ltd. have completed a merger, bringing together their expertise in biopharmaceuticals and cell therapy. Following the merger, the ITOL-102 cell therapy program for Type 1 Diabetes, originally supported by a grant from the Israel-U.S. Binational Industrial Research and Development  Foundation, will continue development under the combined company. The collaboration aims to leverage Kadimastem's advanced stem-cell platform to expand the new pipeline into regenerative and metabolic medicine, with ongoing support from the BIRD Foundation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Ga","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDLbsPGlM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLSP","BK4007","NCEL"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}